NASDAQ:FENC - Fennec Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $7.58 +0.14 (+1.88 %) (As of 02/17/2019 01:05 AM ET)Previous Close$7.58Today's Range$7.35 - $7.6452-Week Range$5.33 - $14.99Volume38,829 shsAverage Volume37,313 shsMarket Capitalization$150.81 millionP/E Ratio-16.13Dividend YieldN/ABeta0.11 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina. Receive FENC News and Ratings via Email Sign-up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FENC Previous Symbol CUSIPN/A Webwww.fennecpharma.com Phone919-636-4530Debt Debt-to-Equity RatioN/A Current Ratio12.04 Quick Ratio12.04Price-To-Earnings Trailing P/E Ratio-16.13 Forward P/E Ratio-15.16 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.68 per share Price / Book4.51Profitability EPS (Most Recent Fiscal Year)($0.47) Net Income$-7,040,000.00 Net MarginsN/A Return on Equity-36.74% Return on Assets-34.74%Miscellaneous Employees3 Outstanding Shares19,896,000Market Cap$150.81 million OptionableOptionable Fennec Pharmaceuticals (NASDAQ:FENC) Frequently Asked Questions What is Fennec Pharmaceuticals' stock symbol? Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC." How were Fennec Pharmaceuticals' earnings last quarter? Fennec Pharmaceuticals Inc (NASDAQ:FENC) released its quarterly earnings data on Tuesday, November, 13th. The company reported ($0.14) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.01. View Fennec Pharmaceuticals' Earnings History. When is Fennec Pharmaceuticals' next earnings date? Fennec Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 25th 2019. View Earnings Estimates for Fennec Pharmaceuticals. What price target have analysts set for FENC? 4 analysts have issued 1-year price targets for Fennec Pharmaceuticals' shares. Their predictions range from $16.00 to $18.00. On average, they expect Fennec Pharmaceuticals' share price to reach $17.00 in the next twelve months. This suggests a possible upside of 124.3% from the stock's current price. View Analyst Price Targets for Fennec Pharmaceuticals. What is the consensus analysts' recommendation for Fennec Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fennec Pharmaceuticals. What are Wall Street analysts saying about Fennec Pharmaceuticals stock? Here are some recent quotes from research analysts about Fennec Pharmaceuticals stock: 1. HC Wainwright analysts commented, "In our view, PEDMARK is worth roughly $430M to Fennec based on a risk-adjusted net present value (NPV) calculation that employs a 12% discount rate, 85% probability of success and a 26% effective tax rate." (12/10/2018) 2. According to Zacks Investment Research, "Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients. The Company's products include Eniluracil and Sodium Thiosulfate (STS). Fennec Pharmaceuticals Inc., formerly known as Adherex Technologies Inc., is based in United States. " (11/28/2018) Has Fennec Pharmaceuticals been receiving favorable news coverage? Press coverage about FENC stock has trended neutral recently, according to InfoTrie. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Fennec Pharmaceuticals earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. Who are some of Fennec Pharmaceuticals' key competitors? Some companies that are related to Fennec Pharmaceuticals include Osiris Therapeutics (OSIR), PDL BioPharma (PDLI), Adaptimmune Therapeutics (ADAP), Replimune Group (REPL), Agenus (AGEN), Nightstar Therapeutics (NITE), Translate Bio (TBIO), DBV TECHNOLOGIE/S (DBVT), Scholar Rock (SRRK), Mesoblast (MESO), MeiraGTx (MGTX), Cellular Biomedicine Group (CBMG), Voyager Therapeutics (VYGR), CASI Pharmaceuticals (CASI) and Gamida Cell (GMDA). Who are Fennec Pharmaceuticals' key executives? Fennec Pharmaceuticals' management team includes the folowing people: Mr. Rostislav Raykov, Pres, CEO & Director (Age 42)Mr. Robert C. Andrade, Chief Financial Officer (Age 43)Mr. Mark Gowland, ControllerMr. Lei Fang, Pres of Pharstat IncMs. Anne McKay, Regulatory Consultant (Age 64) Who are Fennec Pharmaceuticals' major shareholders? Fennec Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include venBio Select Advisor LLC (5.56%), Opaleye Management Inc. (4.52%), BlackRock Inc. (2.83%), United Services Automobile Association (0.77%), Geode Capital Management LLC (0.20%) and Weiss Multi Strategy Advisers LLC (0.13%). Company insiders that own Fennec Pharmaceuticals stock include Manchester Management Pr, Llc and Spa Essetifin. View Institutional Ownership Trends for Fennec Pharmaceuticals. Which major investors are selling Fennec Pharmaceuticals stock? FENC stock was sold by a variety of institutional investors in the last quarter, including Opaleye Management Inc. and Bronfman E.L. Rothschild L.P.. View Insider Buying and Selling for Fennec Pharmaceuticals. Which major investors are buying Fennec Pharmaceuticals stock? FENC stock was purchased by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, United Services Automobile Association, Weiss Multi Strategy Advisers LLC, Rhumbline Advisers, Geode Capital Management LLC and BlackRock Inc.. View Insider Buying and Selling for Fennec Pharmaceuticals. How do I buy shares of Fennec Pharmaceuticals? Shares of FENC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Fennec Pharmaceuticals' stock price today? One share of FENC stock can currently be purchased for approximately $7.58. How big of a company is Fennec Pharmaceuticals? Fennec Pharmaceuticals has a market capitalization of $150.81 million. The company earns $-7,040,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. Fennec Pharmaceuticals employs 3 workers across the globe. What is Fennec Pharmaceuticals' official website? The official website for Fennec Pharmaceuticals is http://www.fennecpharma.com. How can I contact Fennec Pharmaceuticals? Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The company can be reached via phone at 919-636-4530. MarketBeat Community Rating for Fennec Pharmaceuticals (NASDAQ FENC)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 85 (Vote Outperform)Underperform Votes: 80 (Vote Underperform)Total Votes: 165MarketBeat's community ratings are surveys of what our community members think about Fennec Pharmaceuticals and other stocks. Vote "Outperform" if you believe FENC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FENC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/17/2019 by MarketBeat.com StaffFeatured Article: Do You Need a Fiduciary?